Traditionally, endocrine research evolved from the phenotypical characterisation of endocrine disorders to the identification of underlying molecular pathophysiology. This approach has been, and still is, extremely successful. The introduction of genomics and proteomics has resulted in a reversal of this sequence of endocrine research: reverse endocrinology. This approach has provided endocrinology with powerful tools to dissect novel molecular pathways involved in health and disease and to identify new drug targets, like the peroxisome-proliferator activated receptor (PPAR) nuclear receptor family. The reiterative combination of innovative genomics and proteomics, and classical endocrine approaches will enable maintenance of endocrinology as a front-runner in biological research and innovate therapeutical approaches in a continuing interaction between bed and bench.